Small Molecule Development & Manufacturting at Quotient Sciences

Seminar: From Bench to Bedside: Accelerating Early Drug Development Through with an Integrated, Multi-Phase Development Partner

Copenhagen, Demark | 16 October 2025
Overview

From Bench to Bedside: Accelerating Early Drug Development Through with an Integrated, Multi-Phase Development Partner

Join us for our upcoming seminar, "From Bench to Bedside: Accelerating Early Drug Development Through with an Integrated, Multi-Phase Development Partner". Taking place in Copenhagen on 16th October, this event will explore the critical transition of a new drug from candidate nomination through to proof of concept studies, highlighting the scientific and operational strategies that drive successful early-phase programs.

The opening presentation, led by Dr. Andrew Parker, Senior Drug Development Consultant, will delve into the preclinical-to-first-in-human (FIH) transition, emphasizing the role of predictive modelling in risk assessment, solubility profiling, and formulation screening. Practical application of these insights will be demonstrated through examples from Quotient Sciences, which enables more informed early-stage decisions.

Following this, John McDermott, VP of Scientific Consulting, will address formulation selection and drug product supply strategies, for the first-in-human protocol. The session will discuss the implementation of innovative drug development strategies, supported by real-world examples of Translational Pharmaceutics® in accelerating the journey from FIH to PoC. It will explore how integrated patient supply solutions—like adaptive manufacturing processes that ensure rapid clinical supply changes—can streamline program execution and enhance flexibility throughout early clinical trials.

This seminar is exclusive in access to industry experts and innovative methodologies. Interactive Q&A sessions with leading scientists from Quotient Sciences will provide attendees with direct insights and practical solutions to common early-phase challenges. By blending expert guidance with actionable case studies, the event offers a unique opportunity to optimize molecule readiness and delivery in early clinical development.

Space is limited! Register your interest to attend our seminar. If you have any questions or difficulty registering, reach out to [email protected].

*We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.

Register
Location
Symbion Science Park
Fruebjergvej 3 2100 København Ø
Copenhagen, Demark

Meet our experts:

We look forward to meeting you at the seminar.

Dr. Andrew Parker

Senior Drug Development Consultant

Dr. Andrew Parker has over two decades of experience in the pharmaceutical industry, spanning from preclinical development, throug...

About Andrew
John McDermott

VP, Scientific Consulting

John McDermott leads Quotient Sciences' global drug development consulting, research fellows, modeling & simulation, and clien...

About John

Learn more about Translational Pharmaceutics:

Read more
News & Announcements, Articles & Publications, Translational Pharmaceutics®, Dr. Asma Patel, Matt Paterson Dr. Asma Patel and Matt Pa­terson contribute to Drug Development & Delivery's special feature, 'Outsourcing Formulation Development & Manufacturing' By: Dr. Asma Patel and Matt Paterson
Learn More
Articles & Publications, Translational Pharmaceutics®, Formulation Development, Dr. Vanessa Zann Dr. Vanessa Zann contributes to Drug Development & Delivery special feature on bioavailability & solubility By: Dr. Vanessa Zann
Learn More
News & Announcements, Translational Pharmaceutics®, Articles & Publications BioPharm International interviews Helen Baker about how Quotient Sciences is optimizing drug development
Learn More
Get in touch
Humanity can't afford to wait, so neither can we.